JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
Current status and potential future of PAI-1 inhibitors
Abstract
PAI-1 is an important factor in the fibrinolytic system. It is also involved in the etiopathogenesis of atherosclerotic processes, metabolic syndrome, obesity, and a significant number of solid and some of the hematological malignancies and even has valuable prognostic value. In this article, we review involvement of PAI-1 in areas other than the fibyrinolytic system, its roles, and its potential contribution to regulatory mechanisms and inhibition pathways. Many important studies proved that PAI-1 is significantly increased in obesity, metabolic syndrome, a significant proportion of malignancies. Although cell culture studies, in vivo studies and animal experiments have provided data on PAI-1 inhibition and models that block the pathways through which PAI-1 is metabolized and acts, suggesting that this blockade can reverse tumor progression, improve metabolic syndrome parameters and improve atherosclerotic processes, the results of these inhibitory agents in humans are still unknown and worth investigating. The upcoming phase 1-2 studies will answer these questions.

Keywords : PAI-1, PAI-1 inhibitors, malignancies, potential, metabolic syndrome

Download Article


1. Cesarman-Maus G, & Hajjar K.A. Molecular mechanisms offibrinolysis.Br J Haematol.2005;129(3):307-321.
2. Lijnen HR. Elements of the fibrinolytic system.Ann N Y Acad Sci.2001;936(1):226-236.
3. Erickson, LA, Hekman CM, Loskutoff, DJ. The primaryplasminogen-activator inhibitors in endothelial cells, platelets,serum, and plasma are immunologically related. Proc Natl AcadSci U S A. 1985;82(24):8710-8714.
4. Tashiro Y, Nishida C, Sato-Kusubata K, et al. Inhibition of PAI-1induces neutrophil-driven neoangiogenesis and promotes tissueregeneration via production of angiocrine factors in mice.Blood.2012;119(26):6382-6393.
5. Zorio E, Gilabert-Estelles J, Espana F, Ramon LA, Cosin R, EstellesA. Fibrinolysis: the key to new pathogenetic mechanisms.CurrMed Chem.2008;15(9):923-929.
6. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from itsdiscovery to its potential role in cell motility and disease.ThrombHaemost. 2005;93(4):631-640.
7. Sillen M, Miyata T, Vaughan DE, Strelkov SV, Declerck PJ.Structural insight into the two-step mechanism of PAI-1 inhibition by small molecule TM5484.Int J Mol Sci.2021;22(3):1482.
8. Dan T, Ichimura A, Pelisch N, Miyata K, Akahori K, MiyataT. Plasminogen activator inhibitor-1 (PAI-1) molecule: newphysiological roles and clinical applications.Japanese journal ofclinical hematology.2014;55(4):396-404.
9. Baluta MM, Vintila MM. PAI-1 inhibition-another therapeuticoption for cardiovascular protection.Maedica.2015;10(2):147-152.
10. Sillen, M., & Declerck, P. J. Targeting PAI-1 in cardiovasculardisease: structural insights into PAI-1 functionality andinhibition.Front Cardiovasc Med. 2020;22(7):622473.
11. Ibrahim AA, Yahata T, Onizuka M, et al. Inhibition ofplasminogen activator inhibitor type-1 activity enhancesrapid and sustainable hematopoietic regeneration.StemCells.2014;32(4): 946-958.
12. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role ofadipose production of plasminogen activator inhibitor-1.Int JObes Relat Metab Disord. 2004;28(11), 1357-1364.
13. Harada K, Yahata T, Onizuka M, Kikkawa E, Miyata T,Ando K. Plasminogen activator inhibitor type-1 is a negativeregulator of hematopoietic regeneration in the adipocyte-rich bone marrow microenvironment.Biochem Biophys ResCommun.2021:(557):180-186.
14. Yahata T, Ibrahim AA, Muguruma Y, et al.TGF-β-inducedintracellular PAI-1 is responsible for retaining hematopoieticstem cells in the niche.Blood. 2017;130(21):2283-2294.
15. Sasaki K, Fujiwara T, Ochi T, Ono K, Kato H, Onodera K,Harigae H. TM5614, an inhibitor of plasminogen activatorinhibitor-1, exerts an antitumor effect on chronic myeloidleukemia.Tohoku J Exp Med.2022;257(3):211-224.
16. Geis T, Döring C, Popp R, et al. HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellularcarcinoma.Exp Cell Res. 2015;331(1):46-57.
17. Hirahata M, Osaki M, Kanda Y, et al. PAI-1, a target gene ofmiR-143, regulates invasion and metastasis by upregulatingMMP-13 expression of human osteosarcoma.Cancer med.2016;(5):892-902.
18. Lampelj M, Arko D, Sikosek C, et al. Urokinase plasminogenactivator (uPA) and plasminogen activator inhibitor type-1(PAI-1) in breast cancer-correlation with traditional prognosticfactors.Radiol oncol.2015;49(4):357-364.
19. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator (uPA) and plasminogen activatorinhibitor type 1 (PAI-1) in tissue and serum of head andneck squamous cell carcinoma patients.Eur J Cancer.1998;34(8):1193-1197.
20. Herszenyi L, Plebani M, Cardin R, et al. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastriccancer.Acta Physiol Hung.1995;83(3):213-221.
21. Mashiko S., Kitatani K, Toyoshima M, et al. Inhibition ofplasminogen activator inhibitor-1 is a potential therapeuticstrategy in ovarian cancer.Cancer Biol Ther. 2015;16(2):253-260.
22. Takayama Y, Hattori N, Hamada H, et al. Inhibition of PAI-1limits tumor angiogenesis regardless of angiogenic stimuli inmalignant pleural mesothelioma.Cancer Res. 2016;76(11): 3285-3294.
23. Lee YC, Yu CC, Lan C, et al. Plasminogen activator inhibitor-1as regulator of tumor-initiating cell properties in head and neckcancers.Head Neck.2016;38(1):E895-E904.
24. Mutoh M, Niho N, Komiya M, et al. Plasminogen activatorinhibitor-1 (Pai-1) blockers suppress intestinal polyp formationin Min mice.Carcinogenesis.2008;29(4):824-829.
25. Placencio VR, Ichimura A, Miyata T, DeClerck YA. Smallmolecule inhibitors of plasminogen activator inhibitor-1 elicitanti-tumorigenic and anti-angiogenic activity.PLoS One.2015;10(7):e0133786.
26. Fang H, Placencio VR, DeClerck YA. Pro-tumorigenic activityof plasminogen activtor inhibitor-1 through an anti-apoptoticfunction.Cancer Res. 2012;104(19):1474-1484
27. Fortenberry YM, Brandal SM, Carpentier G, Hemani M, PathakAP. Intracellular expression of PAI-1 specific aptamers altersbreast cancer cell migration, invasion and angiogenesis.PLoSOne. 2016;11(10), 0164288.
28. Masuda T, Hirata T, Sakamoto T. Treatment rationale andprotocol design: an investigator-initiated phase II study ofcombination treatment of nivolumab and TM5614, a PAI-1inhibitor for previously treated patients with non-small celllung cancer.J Thorac Dis.2024;16(5):3381-3388.
29. Tzekaki EE, Geromichalos G, Lavrentiadou SN, et al.Oleuropein is a natural inhibitor of PAI-1-mediatedproliferation in human ER-/PR-breast cancer cells.BreastCancer Res Treat.2021;(186):305-316.
30. Agirbasli, M. Pivotal role of plasminogen-activator inhibitor 1in vascular disease.Int J Clin Pract. 2005;59(1):102-106.
31. Brown, NJ, Agirbasli A, Williams GH, Litchfield WR, VaughanDE. Effect of activation and inhibition of the renin-angiotensinsystem on plasma PAI-1.Hypertension.1998;32(6): 965-971.
32. Agirbasli M, Eren M, Eren F, et al. Enhanced functional stabilityof plasminogen activator inhibitor-1 in patients with livedoidvasculopathy.J Thromb Thrombolysis. 2011;(32):59-63.
33. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin,cardiovascular outcomes, and mortality in type 2 diabetes.NEngl J Med. 2015;373(22):2117-2128.
34. Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y.Empagliflozin decreases the plasma concentration ofplasminogen activator inhibitor-1 (PAI-1) in patients withtype 2 diabetes: association with improvement of fibrinolysis.JDiabetes Complications.2020;34(11):107703.
35. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE.Factors responsible for impaired fibrinolysis in obese subjectsand NIDDM patients.Diabetes.1994;43(1):104-109.
36. Skurk, T, Lee YM, Nicuta-Rölfs TO, Haastert B, Wirth A, HaunerH. Effect of the angiotensin II receptor blocker candesartanon fibrinolysis in patients with mild hypertension.Diabetes,Obesity and Metab. 2004;6(1):56-62.
37. Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazoneon fibrinolysis and activated coagulation in patients withnon-insulin-dependent diabetes mellitus.J DiabetesComplications.1998;12(4):181-186.
38. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects oftroglitazone on blood concentrations of plasminogen activatorinhibitor 1 in patients with type 2 diabetes and in lean andobese normal subjects.Diabetes.2000;49(4):633-639.
39. Charles MA, Morange P, Eschwège E, et al. Effect of weightchange and metformin on fibrinolysis and the von willebrandfactor in obese nondiabetic subjects: the BIGPRO1 study.biguanides and the prevention of the risk of obesity.Diabetes.1998;21(11):1967-1972.
40. Erdem Y, Usalan C, Haznedaroğlu ÍC, Altun B, Arici M, YasavulÜ, Çağlar S. Effects of angiotensin converting enzyme andangiotensin II receptor inhibition on impaired fibrinolysis insystemic hypertension.Am J Hypertens.1999;12(11):1071-1076.
41. Lindahl B, Nilsson TK, Jansson JH, Asplund K, HallmansG. Improved fibrinolysis by intense lifestyle intervention. Arandomized trial in subjects with impaired glucose tolerance.Jintern med.1999;246(1):105-112.
Article available in :
Volume 2, Issue 3, 2024
Page : 72-75
https://doi.org/10.51271/JCHOR-0042
Article Information
Received : 04 Haz 2024
Accepted : 25 Haz 2024
Published : 01 Ağu 2024
Corresponding Author :

Taner Tan: Department of Hematology, Faculty of Medicine, Koç University, İstanbul, Turkiye

[email protected]
Citation : Tan T, Ağırbaşlı M. Current status and potential future of PAI-1 inhibitors. J Curr Hematol Oncol Res. 2024;2(3): 72-75.

Read: 354
Cited: 0
Download : 107
_Footer